CD151 and neoplasm: As high CD151 levels predict high malignancy and low sorafenib sensitivity simultaneously, this underlines the substantial heterogeneity between high and low CD151 levels in HCC and the importance of assessing the molecular type of tumor when choosing a treatment regimen.